{"entity":{"id":"nct05702229","kind":"trial","name":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","aka":[],"tldr":"A phase 2 trial of Rilvegostomig, CAPOX (capecitabine, oxaliplatin) and Capecitabine in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, now recruiting.","summary":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma is a phase 2 interventional study registered as NCT05702229 by AstraZeneca, with 163 participants planned, started 2023-01-16 and due to reach its primary completion in 2027-11-30. Interventions recorded: Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD0901 and 5-Fluorouracil.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05702229","url":"https://clinicaltrials.gov/study/NCT05702229"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["rilvegostomig","capox","capecitabine"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05702229","phase":"2","setting":"An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","sponsor":"AstraZeneca","participation":[{"nct":"NCT05702229","source":"https://clinicaltrials.gov/study/NCT05702229","fetchedAt":"2026-10-07T16:53:52.193Z","studySha256":"d9d871799a511ecbcc7904456614eea09a6418e72f21729f4bc5ca8f5ee6e90f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-14","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":163,"enrolmentType":"ESTIMATED","siteCount":44,"recruitingSiteCount":35,"countries":["China","Japan","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2023-01-16","startedType":"actual","enrolled":163,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05702229/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}